sorafenib has been researched along with hesperetin in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (hesperetin) | Trials (hesperetin) | Recent Studies (post-2010) (hesperetin) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 585 | 15 | 417 |
| Protein | Taxonomy | sorafenib (IC50) | hesperetin (IC50) |
|---|---|---|---|
| Cytochrome P450 1A1 | Homo sapiens (human) | 2.786 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | 8.3 | |
| Dipeptidyl peptidase 4 | Homo sapiens (human) | 0.28 | |
| Cytochrome P450 1B1 | Homo sapiens (human) | 0.511 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eltelbany, RFA; Khalil, HMA; Rasheed, RA; Zaafar, D; Zaitone, SA | 1 |
1 other study(ies) available for sorafenib and hesperetin
| Article | Year |
|---|---|
Hesperetin mitigates sorafenib-induced cardiotoxicity in mice through inhibition of the TLR4/NLRP3 signaling pathway.
Topics: Animals; Cardiotoxicity; Hesperidin; Interleukin-6; Male; Mice; NLR Family, Pyrin Domain-Containing 3 Protein; Signal Transduction; Sorafenib; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2022 |